We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. For patients with hepatitis C genotype 4, treatment with ...
Gilead Sciences announced results from ION-4, a Phase 3 study evaluating Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for the treatment of genotypes 1 or 4 chronic hepatitis C virus (HCV) infection ...
AbbVie announced that the Food and Drug Administration (FDA) has approved Technivie (ombitasvir, paritaprevir, ritonavir) tablets in combination with ribavirin for the treatment of adults with ...
In this issue of JGH, Chehadeh et al. report their investigation into risk factors for the development of type 2 diabetes mellitus (T2D) in chronic hepatitis C virus (HCV) genotype 4 infection among ...
Expert Rev Gastroenterol Hepatol. 2009;3(6):607-13. For genotype 1 and 4 hepatitis C virus infections, the standard treatment is pegylated (PEG)-IFN-α plus weight-adjusted ribavirin (RBV) doses for 48 ...
Results of multivariable logistic regression performed on more than 3000 patients showed that steatosis was associated independently with HCV genotype 3 (OR, 4.24; P <.001). 17 Recent data also show ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Suboptimal treatment response in chronic ...
The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 ...
Background. Few direct anti–hepatitis C virus (HCV) agents have been studied in difficult-to-treat null responder and cirrhotic human immunodeficiency virus (HIV)-coinfected patients. Daclatasvir and ...
The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in ...
ALEXANDRIA, Egypt--(BUSINESS WIRE)--Egypt’s leading drug manufacturer Pharco Pharmaceuticals, Inc. announced advanced results today from its Phase III clinical trial of the combination of ravidasvir ...
We hypothesized that in patients with hepatitis C virus (HCV) genotype 2 or 3 in whom HCV RNA is not detectable after 4 weeks of therapy, 12 weeks of treatment is as effective as 24 weeks. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results